Top

Digestive Diseases and Sciences

Published in:

01-08-2011 | Original Article

Differentiation-Inducing Activity of Hydroxycamptothecin on Cancer Stem-Like Cells Derived from Hepatocellular Carcinoma

Authors: Yi Zhang, Wen-Jie Song, Fu-Qin Zhang, Wei-Hui Liu, Ke-Feng Dou

Published in: Digestive Diseases and Sciences | Issue 8/2011

Abstract

Background

Hydroxycamptothecin (HCPT) is an anti-tumor agent that can induce differentiation in human cancer cells. Recent evidence indicates that side population (SP) cells possess characteristics of stem-like cells, and may be capable of initiating tumor growth.

Aims

The present study investigated the differentiation of cancer stem-like cells derived from hepatocellular carcinoma.

Methods and Results

Flow cytometry was used to isolated SP cells from HCC cell line (MHCC97 cells). These SP cells exhibit several stem-like cell characteristics that are distinct from the main population (MP) cells in vitro. After 3 days of induction with a low concentration of HCPT, the SP cells lost their capacity to proliferate and invade, and their tumorigenicity declined. Based on real-time quantitative RT-PCR, we also found that the expression of hepatocyte-specific markers such as α-fetoprotein, albumin, hepatocyte nuclear factor-4 and miR-122 gradually changed during the differentiation of SP cells.

Conclusions

Our data suggest that a low concentration of HCPT can induce hepatocyte-specific differentiation of cancer stem-like cells from MHCC97 cells, offering a possible therapeutic strategy for the treatment of human malignancies.

Dawe RS. Hepatocellular carcinoma. Lancet. 2004;363:899.PubMedCrossRef

Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373:614–616.PubMedCrossRef

Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–1261.PubMedCrossRef

Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells—old concepts, new insights. Cell Death Differ. 2008;15:947–958.PubMedCrossRef

Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542–2556.PubMedCrossRef

Hussain SZ, Strom SC, Kirby MR, et al. Side population cells derived from adult human liver generate hepatocyte-like cells in vitro. Dig Dis Sci. 2005;50:1755–1763.PubMedCrossRef

Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67:4827–4833.PubMedCrossRef

Harris MA, Yang H, Low BE, et al. Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res. 2008;68:10051–10059.PubMedCrossRef

Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006;44:240–251.PubMedCrossRef

10.

Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol. 2003;3:338–343.PubMedCrossRef

11.

Lin TL, Vala MS, Barber JP, et al. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia. 2007;21:1915–1920.PubMedCrossRef

12.

Waxman S. Differentiation therapy in acute myelogenous leukemia (non-apl). Leukemia. 2000;14:491–496.PubMedCrossRef

13.

Kawamata H, Tachibana M, Fujimori T, Imai Y. Differentiation-inducing therapy for solid tumors. Curr Pharm Des. 2006;12:379–385.PubMedCrossRef

14.

Kondo K, Tsuneizumi K, Watanabe T, Oishi M. Induction of in vitro differentiation of mouse embryonal carcinoma (f9) cells by inhibitors of topoisomerases. Cancer Res. 1991;51:5398–5404.PubMed

15.

Jing Y, Hashimoto S, Nakajo S, Nakaya K. Topoisomerase inhibitors potentiate the effect of retinoic acid on cell growth inhibition and induction of differentiation of leukemia hl-60 cells. Leuk Res. 1994;18:299–304.PubMedCrossRef

16.

Santos A, Calvet L, Terrier-Lacombe MJ, et al. In vivo treatment with cpt-11 leads to differentiation of neuroblastoma xenografts and topoisomerase i alterations. Cancer Res. 2004;64:3223–3229.PubMedCrossRef

17.

Kamiya A, Gonzalez FJ, Nakauchi H. Identification and differentiation of hepatic stem cells during liver development. Front Biosci. 2006;11:1302–1310.PubMedCrossRef

18.

van der Zee AG, de Jong S, Keith WN, et al. Quantitative and qualitative aspects of topoisomerase i and ii alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res. 1994;54:749–755.PubMed

19.

Boonsong A, Curran S, McKay JA, et al. Topoisomerase i protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol. 2002;33:1114–1119.PubMedCrossRef

20.

Gouveris P, Lazaris AC, Papathomas TG, et al. Topoisomerase i protein expression in primary colorectal cancer and recurrences after 5-fu-based adjuvant chemotherapy. J Cancer Res Clin Oncol. 2007;133:1011–1015.PubMedCrossRef

21.

Ling YH, Tseng MT, Nelson JA. Differentiation induction of human promyelocytic leukemia cells by 10-hydroxycamptothecin, a DNA topoisomerase i inhibitor. Differentiation. 1991;46:135–141.PubMedCrossRef

22.

Zhang XW, Jiang JF, Xu B. Differentiation-inducing action of 10- hydroxycamptothecin on human hepatoma hep g2 cells. Acta Pharmacol Sin. 2000;21:364–368.PubMed

23.

Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004;101:14228–14233.PubMedCrossRef

24.

Wu C, Wei Q, Utomo V, et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res. 2007;67:8216–8222.PubMedCrossRef

25.

Shackleton M. Normal stem cells and cancer stem cells: similar and different. Semin Cancer Biol. 2010;20:85–92.PubMedCrossRef

26.

Fulda S, Pervaiz S. Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol. 2010;42:31–38.PubMedCrossRef

27.

Gilbert CA, Ross AH. Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem. 2009;108:1031–1038.PubMedCrossRef

28.

Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–284.PubMedCrossRef

29.

Patrawala L, Calhoun T, Schneider-Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas abcg2+ and abcg2− cancer cells are similarly tumorigenic. Cancer Res. 2005;65:6207–6219.PubMedCrossRef

30.

Hu C, Li H, Li J, et al. Analysis of abcg2 expression and side population identifies intrinsic drug efflux in the hcc cell line mhcc-97l and its modulation by akt signaling. Carcinogenesis. 2008;29:2289–2297.PubMedCrossRef

31.

Polgar O, Robey RW, Bates SE. Abcg2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol. 2008;4:1–15.PubMedCrossRef

32.

Chen Z, Liu F, Ren Q, et al. Suppression of abcg2 inhibits cancer cell proliferation. Int J Cancer. 2010;126:841–851.PubMed

33.

Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 2003;31:1035–1042.PubMedCrossRef

34.

Jones EA, Clement-Jones M, James OF, Wilson DI. Differences between human and mouse alpha-fetoprotein expression during early development. J Anat. 2001;198:555–559.PubMedCrossRef

35.

Li J, Ning G, Duncan SA. Mammalian hepatocyte differentiation requires the transcription factor hnf-4alpha. Genes Dev. 2000;14:464–474.PubMed

36.

Herbst RS, Nielsch U, Sladek F, et al. Differential regulation of hepatocyte-enriched transcription factors explains changes in albumin and transthyretin gene expression among hepatoma cells. New Biol. 1991;3:289–296.PubMed

37.

Bai S, Nasser MW, Wang B, et al. Microrna-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009;284:32015–32027.PubMedCrossRef

38.

Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of mir-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28:3526–3536.PubMedCrossRef

Title: Differentiation-Inducing Activity of Hydroxycamptothecin on Cancer Stem-Like Cells Derived from Hepatocellular Carcinoma
Authors: Yi Zhang
Wen-Jie Song
Fu-Qin Zhang
Wei-Hui Liu
Ke-Feng Dou
Publication date: 01-08-2011
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 8/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-011-1601-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Aims

Methods and Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2011

CT Portography with Gastric Variceal Volume Measurements in the Evaluation of Endoscopic Therapeutic Efficacy of Tissue Adhesive Injection into Gastric Varices: A Pilot Study

Drug-Induced Autoimmune-Like Hepatitis: A Diagnostic Challenge

Acute Pancreatitis in Obesity: Adipokines and Dietary Fish Oil

Donor Hepatectomy for Living Donor Liver Transplantation: Learning Steps and Surgical Outcome

Erratum to: Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B

Nicorandil Associated Colonic Ulceration: Case Series of an Increasingly Recognized Complication

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials